Predictors of In-hospital Adverse Events in Patients with Prosthetic Valve Infective Endocarditis

Heart, Lung & Circulation
Hwee-Leong TanKian-Keong Poh

Abstract

We aimed to study patients with prosthetic valve endocarditis (PVE) and analyse factors associated with in-hospital adverse events. A review of all patients who underwent echocardiography at a local university hospital with definite PVE (modified Duke's criteria) was performed. Adverse events of in-hospital mortality and redo valve surgery were identified. There were 23 patients with PVE (median age 53 years (IQR:38-66), 12 males (52%)). Twelve adverse events occurred including seven (30%) in-hospital mortalities and five (21%) redo valve surgery. Factors associated with in-hospital mortality include Staphylococcus aureus-PVE (86% vs 31%, p=0.027), presence of shock (86% vs 19%, p=0.005) and intensive care unit admission (72% vs 19%, p=0.026). Factors associated with the need for redo valve surgery include a younger median age (37 vs 61 years, p=0.012), longer median length of stay (58 vs 17 days, p=0.004), history of intravenous drug abuse (IVDA) (60% vs 6%, p=0.021) and right-sided valvular involvement (40% vs 0%, p=0.040). Using a composite endpoint of both outcomes, factors associated with in-hospital adverse events were a history of IVDA (36% vs 0%, p=0.037) and presence of shock (64% vs 17%, p=0.036). PVE carries a high r...Continue Reading

References

Aug 8, 1996·The New England Journal of Medicine·W VongpatanasinR A Lange
Feb 15, 2001·The New England Journal of Medicine·I C Tuna, M R Harrison
Apr 16, 2003·Heart·Rob Moss, Brad Munt
Mar 30, 2007·JAMA : the Journal of the American Medical Association·Andrew WangUNKNOWN International Collaboration on Endocarditis-Prospective Cohort Study Investigators
Dec 25, 2007·Progress in Cardiovascular Diseases·Gilbert HabibJean-François Avierinos
Feb 28, 2009·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·S RekikS Kammoun
Aug 8, 2009·The Journal of Thoracic and Cardiovascular Surgery·Hector Alonso-ValleM Carmen Fariñas
Jan 26, 2010·BMC Infectious Diseases·Juan Gálvez-AcebalUNKNOWN Grupo para el Estudio de las Infecciones Cardiovasculares de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Oct 16, 2010·Asian Cardiovascular & Thoracic Annals·Hee-Hwa HoWing-Hing Chow

❮ Previous
Next ❯

Citations

Dec 18, 2015·Heart, Lung & Circulation·Yong-Qiang Benjamin TanKian Keong Poh
May 20, 2015·International Journal of Cardiology·Qiao-Zhi CheeKian-Keong Poh
Jul 8, 2015·Heart, Lung & Circulation·Birdal Yıldırım, Funda Sungur Biteker

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Revista española de cardiología
Ana RevillaJosé A San Román
JAMA : the Journal of the American Medical Association
Andrew WangInternational Collaboration on Endocarditis-Prospective Cohort Study Investigators
© 2022 Meta ULC. All rights reserved